|Mr. Shai Lankry CPA, M.B.A.||Chief Financial Officer||564k||N/A||1976|
|Ms. Michele Ilene Korfin M.B.A., R.Ph.||Chief Operating & Chief Commercial Officer||510k||N/A||1972|
|Dr. Ronit Simantov M.D.||Chief Medical & Chief Scientific Officer||581k||N/A||1965|
|Dr. Jas Uppal Ph.D.||Chief Regulatory Officer||476k||N/A||1968|
|Ms. Abigail L. Jenkins||Pres, CEO & Director||N/A||N/A||1976|
|Mr. Joshua F. Patterson||Gen. Counsel & Chief Compliance Officer||N/A||N/A||1976|
|Mr. Paul Nee||VP of Marketing||N/A||N/A||N/A|
|Mr. Naftali Brikashvili CPA||Sr. VP Fin. & Operations||N/A||N/A||N/A|
|Dr. Tracey Lodie Ph.D.||Scientific Advisor & Consultant||N/A||N/A||1970|
|Mr. Vladimir Melnikov||Sr. VP of Global Operations & Manufacturing||N/A||N/A||N/A|
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Gamida Cell Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.